Geographic Atrophy Secondary to Age-related Macular Degeneration Clinical Trials
5 recruiting trials for Geographic Atrophy Secondary to Age-related Macular Degeneration. Eligibility criteria explained in plain English.
TrialFinderData lists 5 Geographic Atrophy Secondary to Age-related Macular Degeneration clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 / Phase 2 is the largest group at 50% (1 studies); the largest phase groups are Phase 1 / Phase 2: 1, Phase 2: 1.
Research is led by Complement Therapeutics (2), i-Lumen Scientific AUS PTY LTD (1), Okuvision GmbH (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Transcorneal electrical stimulation (TES) with the OkuStim 2 System (device, 2 trials), followed by i-Lumen AMD, CTx001.
Track Geographic Atrophy Secondary to Age-related Macular Degeneration trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to...
Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
Geographic atrophy (GA) is a progressive eye disease that causes the degeneration of the retinal cells, particularly in the macula, leading to vision loss. The goal of this pilot...
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
This is a non-interventional, observational study to provide insights into the short-term progression of GA secondary to AMD in participants aged ≥55 years. This is a...
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With...
This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD). Safety and...
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics...
Explore Other Conditions
Frequently Asked Questions
There are currently 5 clinical trials for Geographic Atrophy Secondary to Age-related Macular Degeneration, with 5 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Geographic Atrophy Secondary to Age-related Macular Degeneration, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Geographic Atrophy Secondary to Age-related Macular Degeneration, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.